drugset / Trial / NCT05768282

Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia

NCT05768282

Phase 4 Unknown 50 enrolled E-DA Hospital
NaSingle-groupOpen-labelPrevention

Summary

Endoscopic radiofrequency ablation (RFA) has shown good efficacy and safety in eradicating flat-type early esophageal squamous cell neoplasia (ESCN). However, post-RFA stricture is still a major concern, especially when treating long-segment early ESCNs. The aim of this study was to investigate the efficacy and safety of oral prednisolone to prevent post-RFA stricture.

Timeline

Start
2016-01-01
Primary completion
2023-12-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified 30 mg Oral

Indications